Evidence map›Paper›PMID 40392499›Full record

ReviewCellular oncology (Dordrecht, Netherlands)2025

Hepatocyte nuclear factor 4-Alpha: a key regulator in liver carcinogenesis.

Hayam Hamdy, Chang Shen, Jiashun Xu, Die Fan, Yiwen Zhang, Hui Li, Yonglong Wei, Jianwei Sun

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular oncology (Dordrecht, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. A 20 Bp Indel ofAnimals : an open access journal from MDPI · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Hayam Hamdy *Yunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Chang Shen *Yunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Jiashun Xu *Yunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Die FanYunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Yiwen ZhangYunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Hui LiYunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China. lihuidoc@126.com.
Yonglong WeiYunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China. weiyl@ynu.edu.cn.
Jianwei SunYunnan Key Laboratory of Cell Metabolism and Diseases, Center for Life Sciences, School of Life Sciences, The Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China. jwsun@ynu.edu.cn.

Funding

Key Laboratory of Tumor Immunological Prevention and Treatment in Yunnan Province, Yan'an Hospital Affiliated to Kunming Medical University KLTIPT-2023-02 and KLTIPT-2023-03National Natural Science Foundation of China 82273460, 82273089 and 32260167the Yunnan Fundamental Research Projects 202401AS070133 and 202401AS070634Yunnan University KC-23236563
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, associated with viral hepatitis, alcohol consumption, and non-alcoholic fatty liver disease. Hepatocyte nuclear factor 4 alpha (HNF4α), a crucial transcription factor for liver function (glucose and lipid metabolism, bile acid homeostasis, and cellular differentiation), is often dysregulated in HCC progression. This review provides a comprehensive overview of the role of HNF4α in hepatic oncogenesis, providing novel inshight into its regulatory effects on epithelial-mesenchymal transition (EMT), metabolic alterations (including the Warburg effect), cell cycle control, and tumor microenvironment. We also discuss therapeutic strategies targeting HNF4α focusing on restoring metabolic balance and inducing apoptosis. This integrated analysis advances our understanding of HNF4α's contribution to HCC and may pave the way for the development of targeted therapies (Fig. 1).

Indexed as

CarcinogenesisCarcinoma, HepatocellularHepatocyte Nuclear Factor 4Liver NeoplasmsAnimalsEpithelial-Mesenchymal TransitionHumansTumor MicroenvironmentHepatocyte Nuclear Factor 4Epithelial-mesenchymal transitionHepatocellular carcinomaHNF4αProgression

Identifiers

PMID40392499
PMCPMC12238214

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.